Palopegteriparatide
High EvidencePalopegteriparatide (Yorvipath, developed as TransCon PTH) is Ascendis Pharma's once-daily prodrug of parathyroid hormone (1-34). An inert methoxy-PEG carrier is attached to PTH(1-34) through a TransCon linker that auto-cleaves at physiologic pH and temperature, releasing unmodified native-sequence PTH slowly enough to hold hormone levels inside the physiologic range for a full 24 hours. It is the first therapy approved as a true hormone replacement for chronic hypoparathyroidism rather than as an add-on to calcium and active vitamin D: in the Phase 3 PaTHway trial 78.7% of treated adults met a composite endpoint of normal serum calcium plus independence from conventional therapy at week 26, versus 4.8% on placebo. The FDA approved Yorvipath on August 9, 2024.
What It Is
Palopegteriparatide (brand name Yorvipath; developed as TransCon PTH by Ascendis Pharma) is a long-acting prodrug of human parathyroid hormone fragment 1-34 - the same biologically active sequence as teriparatide, delivered on a completely different pharmacokinetic schedule. Chronic hypoparathyroidism is one of the few remaining classical endocrine deficiencies without a routine hormone replacement. Most cases follow neck surgery, when the parathyroid glands are damaged or removed; the rest are autoimmune, genetic, or infiltrative. Without PTH, patients cannot maintain serum calcium, cannot activate vitamin D in the kidney, and cannot conserve calcium in the renal tubule. Standard care - large oral calcium loads plus active vitamin D analogs such as calcitriol - raises serum calcium but does nothing about the missing hormone. It leaves patients with wide daily calcium swings, persistent brain fog, fatigue and paresthesias, and it drives calcium into the urine, where over decades it produces nephrocalcinosis, kidney stones and chronic kidney disease. The problem with replacing PTH directly is that PTH is catabolic when given in pulses and anabolic-to-homeostatic when delivered continuously. Teriparatide injected once or twice daily produces a sharp peak that mobilizes bone and then a long trough of hypocalcemia; the earlier full-length replacement rhPTH(1-84) (Natpara) improved on this but still did not maintain steady physiologic exposure and was withdrawn from the market for manufacturing reasons, leaving patients without an option. TransCon PTH was engineered specifically to solve the exposure-shape problem. The molecule consists of PTH(1-34) bound to an inert methoxy polyethylene glycol carrier through a proprietary TransCon linker. The conjugate itself is inactive and cannot engage the PTH1 receptor; instead the linker hydrolyzes predictably as a function of physiologic pH and temperature, releasing free, unmodified PTH(1-34) at a controlled rate. The effect is an apparent half-life on the order of two and a half days for the released hormone, so a single daily subcutaneous injection produces flat, continuous PTH exposure within the physiologic band rather than a spike-and-crash curve. That is the pharmacology that lets palopegteriparatide restore what the hormone actually does in the body: normalize serum calcium, restore renal calcium reabsorption so that urinary calcium falls, restore endogenous activation of vitamin D, and normalize bone turnover - and therefore allow conventional calcium and active vitamin D to be stopped entirely rather than merely reduced. The pivotal Phase 3 PaTHway trial randomized 82 adults with chronic hypoparathyroidism 2:1 to palopegteriparatide (starting at 18 mcg/day with individualized titration) or placebo, both on optimized conventional therapy. At week 26, 78.7% of the treated group met the composite primary endpoint - albumin-adjusted serum calcium in the normal range, independence from conventional therapy (no active vitamin D and no more than 600 mg/day of elemental calcium), and no increase in study drug dose in the preceding four weeks - versus 4.8% of placebo patients. In the open-label extension through week 52, the large majority of patients remained free of active vitamin D, 24-hour urinary calcium excretion fell substantially from baseline, and patient-reported symptom and quality-of-life scores improved in parallel with the biochemistry, which is the outcome that matters most to people who have lived for years with a normal serum calcium and abnormal daily function. The FDA approved Yorvipath for adults with chronic hypoparathyroidism on August 9, 2024, following European approval, and it became commercially available in the United States in 2025. For PepTracker Pro readers, palopegteriparatide is also the clearest demonstration of Ascendis' TransCon prodrug platform - the same carrier-and-linker approach used in navepegritide (TransCon CNP) for achondroplasia and in lonapegsomatropin for growth hormone deficiency. The lesson generalizes well beyond hypoparathyroidism: for peptide hormones whose biology depends on the shape of the exposure curve rather than on total dose, engineering the release profile can matter more than engineering the molecule.
Regulatory Status
Yorvipath (palopegteriparatide) for injection was approved by the FDA on August 9, 2024 for the treatment of hypoparathyroidism in adults, and had previously been approved in the European Union. It is supplied as a once-daily subcutaneous injection in a multiple-dose prefilled pen across several dose strengths, with individualized titration guided by albumin-adjusted serum calcium. It is a prescription hormone replacement therapy requiring endocrinology supervision and laboratory monitoring - it is not a research chemical, supplement, or over-the-counter product, and it has no legitimate wellness, anti-aging, or performance use.
Effective: August 2024
View FDA SourceWhy Researchers Study It
Palopegteriparatide is the proof that, for some peptide hormones, the shape of the exposure curve is the therapy. PTH(1-34) has been available as teriparatide since 2002, but delivered as a once-daily pulse it is an osteoporosis drug, not a replacement hormone: the peak mobilizes calcium from bone and the long trough leaves patients hypocalcemic. The same peptide, released continuously inside the physiologic range by an auto-cleaving prodrug, becomes something categorically different - it normalizes serum calcium, lowers urinary calcium instead of raising it, restores renal vitamin D activation, and lets patients discontinue the calcium and calcitriol regimens that were never treating the underlying deficiency. Researchers study it for three reasons. First, it closes a real gap: chronic hypoparathyroidism was the last classical endocrine deficiency without routine hormone replacement, and the previous option, rhPTH(1-84), left the market. Second, it is the cleanest clinical validation of the TransCon prodrug platform, which uses the same inert-carrier-plus-cleavable-linker design for CNP in achondroplasia (navepegritide) and growth hormone in pediatric GHD - a template that could be applied to any peptide whose native half-life is too short for its intended biology. Third, its endpoints moved past biochemistry: PaTHway and the PaTH Forward extension paired serum calcium normalization with reductions in 24-hour urinary calcium and with patient-reported symptom and quality-of-life measures, which matters because the chief complaint in this disease - cognitive fog and fatigue - is invisible on a standard calcium panel.
Proposed Mechanisms
- Prodrug design: PTH(1-34) is covalently bound to an inert methoxy-PEG carrier through a TransCon linker; the conjugate is pharmacologically inactive and cannot engage the PTH1 receptor
- Predictable auto-cleavage of the linker driven by physiologic pH and temperature releases free, unmodified native-sequence PTH(1-34) at a controlled rate - no enzymatic activation required
- Continuous rather than pulsatile exposure: the released hormone has an apparent half-life of roughly two and a half days, so once-daily dosing keeps PTH within the physiologic range across the full 24 hours instead of producing a peak-and-trough curve
- Restores renal tubular calcium reabsorption, which lowers 24-hour urinary calcium excretion - the opposite of what high-dose oral calcium plus active vitamin D does
- Restores endogenous 1-alpha-hydroxylation of vitamin D in the kidney, allowing active vitamin D analogs such as calcitriol to be discontinued
- Normalizes bone turnover and phosphate handling, addressing the skeletal and renal consequences of long-term PTH deficiency rather than only the serum calcium number
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 3 (PaTHway, NCT04701203) - randomized, double-blind, placebo-controlled | 82 adults with chronic hypoparathyroidism randomized 2:1 to palopegteriparatide (18 mcg/day starting dose, individualized titration) or placebo, both with optimized conventional therapy, for 26 weeks | Primary composite endpoint met: 78.7% of treated patients versus 4.8% of placebo patients achieved albumin-adjusted serum calcium in the normal range, independence from conventional therapy (no active vitamin D and <=600 mg/day elemental calcium), and no increase in study drug dose in the prior 4 weeks. All key secondary endpoints were also met | Source |
| Phase 3 (PaTHway) - open-label extension, 52-week results | Adults with chronic hypoparathyroidism continuing palopegteriparatide through week 52 | Sustained efficacy, safety and tolerability: the large majority of patients remained independent of active vitamin D with serum calcium in the normal range, 24-hour urinary calcium excretion was substantially reduced from baseline, and biochemical stability was maintained | Source |
| Phase 2 (PaTH Forward) - long-term open-label extension, patient-reported outcomes | Adults with chronic hypoparathyroidism on palopegteriparatide in extended follow-up | Improvements in patient-reported symptom burden and health-related quality-of-life measures accompanied the biochemical response, addressing the cognitive and fatigue complaints that persist in conventionally treated patients despite normal serum calcium | Source |
| Regulatory - FDA approval | U.S. product label for Yorvipath (palopegteriparatide) for injection | Approved August 9, 2024 for the treatment of hypoparathyroidism in adults - the first therapy positioned as PTH replacement rather than as an adjunct to calcium and active vitamin D; U.S. commercial availability followed in 2025 | Source |
| Real-world evidence - U.S. expanded access program | Adults with hypoparathyroidism enrolled in the U.S. expanded access program, followed for up to 12 months on palopegteriparatide | Early real-world data describe reductions in conventional therapy requirements, achieved dosing, serum calcium trajectories and adverse events outside the controlled trial setting, broadly consistent with the registrational findings | Source |
| Clinical - switching from rhPTH(1-84) | Adults with chronic hypoparathyroidism transitioned from rhPTH(1-84) (Natpara) to palopegteriparatide with individual dose adjustment | Published case and short-term switching data describe successful transition with individualized titration, relevant because rhPTH(1-84) was withdrawn from the market and its users required an alternative | Source |
Commonly Discussed Benefits
Researching Palopegteriparatide? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Prescription hormone replacement for a chronic endocrine disease - palopegteriparatide must be prescribed and titrated by a clinician, ideally an endocrinologist, with serial albumin-adjusted serum calcium monitoring. It has no wellness, anti-aging or performance application and should never be sourced outside a pharmacy
- Hypercalcemia and hypocalcemia both occur, most often during titration and during the transition off conventional calcium and active vitamin D; symptomatic or severe swings in either direction can be dangerous and require prompt dose adjustment and laboratory follow-up
- Because the drug restores endogenous vitamin D activation and renal calcium reabsorption, conventional calcium and calcitriol must be tapered deliberately as the dose is titrated - continuing them unchanged risks hypercalcemia
- Common adverse reactions reported in the clinical program include injection-site reactions, headache, diarrhea, paresthesia, hypocalcemia and hypercalcemia; the current U.S. prescribing information should be consulted for the complete and authoritative list
- The PTH-analog class has historically carried warnings derived from rodent osteosarcoma findings; prescribers should consult the current approved labeling for how these are handled for this product rather than relying on secondary sources
- Safety and effectiveness in pediatric patients have not been established in the approved adult indication; pediatric development is ongoing
- Palopegteriparatide is not interchangeable with teriparatide. Teriparatide is a pulsatile once-daily osteoporosis therapy; palopegteriparatide delivers continuous physiologic PTH exposure for replacement. Substituting one for the other is a clinically meaningful error
- Long-term outcome data on the endpoints that matter most in this disease - nephrocalcinosis, kidney stones, progression of chronic kidney disease and fracture risk over decades - are still accumulating
Comparisons
See how Palopegteriparatide compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial - Journal of Clinical Endocrinology & Metabolism (2025) PubMed
- [2] FDA Approves YORVIPATH (palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults - Ascendis Pharma PubMed
- [3] Drug Trials Snapshots: YORVIPATH - U.S. Food and Drug Administration PubMed
- [4] YORVIPATH (palopegteriparatide) Now Commercially Available in the United States - Ascendis Pharma PubMed
- [5] Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension - Journal of Clinical Endocrinology & Metabolism (2026) PubMed
- [6] Advancing hypoparathyroidism treatment: FDA approval of palopegteriparatide as a promising orphan drug - PMC PubMed
- [7] Early U.S. Real-World Treatment Patterns and Outcomes in Palopegteriparatide Treatment for Patients With Hypoparathyroidism - Endocrine Practice PubMed
Keep researching in the app
- Log Palopegteriparatide to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Navepegritide
High EvidenceA C-type natriuretic peptide (CNP) analog FDA-approved in February 2026 for increasing linear growth in children with achondroplasia — the first once-weekly CNP therapy.
Setmelanotide
High EvidenceA once-daily subcutaneous cyclic octapeptide melanocortin-4 receptor (MC4R) agonist, FDA-approved for several rare genetic and acquired forms of obesity that act through the leptin-melanocortin pathway.
Glepaglutide
Medium EvidenceA long-acting glucagon-like peptide-2 (GLP-2) analog given by once- or twice-weekly subcutaneous injection that helps the gut absorb more nutrients in short bowel syndrome, reducing dependence on IV (parenteral) nutrition.
Vosoritide
High EvidenceA once-daily subcutaneous peptide (a 39-amino-acid analog of C-type natriuretic peptide, CNP) that is the first approved medicine to increase linear growth in children with achondroplasia. Marketed by BioMarin as Voxzogo, it works one step downstream of the overactive FGFR3 receptor that causes achondroplasia: by binding natriuretic peptide receptor-B (NPR-B), it dampens FGFR3's braking signal on the growth plate and lets cartilage cells proliferate and mature normally. First FDA-approved in November 2021 for children 5 and older with open growth plates, its label was expanded in 2023 to cover children under 5 (all ages with open growth plates). In 2026 BioMarin reported new long-term and early-treatment data and advanced a once-weekly successor CNP peptide, BMN 333.
Trofinetide
High EvidenceA twice-daily oral peptide analog of the IGF-1 tripeptide glycine-proline-glutamate (GPE) that is the first and only medicine approved to treat Rett syndrome. Marketed by Acadia Pharmaceuticals as Daybue, trofinetide does not correct the underlying MECP2 mutation; instead it works on the downstream consequences - it is thought to restore synaptic signaling, dampen neuroinflammation, and normalize overactive microglia and astrocytes, improving neurobehavioral symptoms. It won FDA approval in March 2023 for adults and children 2 years and older. In late 2025 the FDA cleared a dye- and preservative-free powder formulation (Daybue STIX, broadly available in April 2026), and in June 2026 the EMA's CHMP adopted a positive opinion recommending European authorization.
Abaloparatide
High EvidenceAbaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label.